ANGION BIOMEDICA CORP (ANGN) Fundamental Analysis & Valuation

NASDAQ:ANGN • US03476J1079

Current stock price

1 USD
+0.02 (+2.04%)
At close:
0.9437 USD
-0.06 (-5.63%)
After Hours:

This ANGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ANGN Profitability Analysis

1.1 Basic Checks

  • ANGN had negative earnings in the past year.
  • In the past year ANGN has reported a negative cash flow from operations.
ANGN Yearly Net Income VS EBIT VS OCF VS FCFANGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

  • ANGN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANGN Yearly ROA, ROE, ROICANGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 200 -200 400

1.3 Margins

  • With an excellent Gross Margin value of 352.37%, ANGN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ANGN has grown nicely.
  • The Profit Margin and Operating Margin are not available for ANGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 352.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5YN/A
ANGN Yearly Profit, Operating, Gross MarginsANGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ANGN Health Analysis

2.1 Basic Checks

  • ANGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ANGN has more shares outstanding
  • Compared to 1 year ago, ANGN has a worse debt to assets ratio.
ANGN Yearly Shares OutstandingANGN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
ANGN Yearly Total Debt VS Total AssetsANGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -0.82, we must say that ANGN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.82, ANGN is in line with its industry, outperforming 53.24% of the companies in the same industry.
  • There is no outstanding debt for ANGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC8.33%
ANGN Yearly LT Debt VS Equity VS FCFANGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • ANGN has a Current Ratio of 20.00. This indicates that ANGN is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 20.00, ANGN belongs to the best of the industry, outperforming 92.13% of the companies in the same industry.
  • A Quick Ratio of 20.00 indicates that ANGN has no problem at all paying its short term obligations.
  • ANGN's Quick ratio of 20.00 is amongst the best of the industry. ANGN outperforms 92.13% of its industry peers.
Industry RankSector Rank
Current Ratio 20
Quick Ratio 20
ANGN Yearly Current Assets VS Current LiabilitesANGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ANGN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 38.28% over the past year.
  • ANGN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -97.79%.
  • The Revenue has been growing by 15.59% on average over the past years. This is quite good.
EPS 1Y (TTM)38.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.3%
Revenue 1Y (TTM)-97.79%
Revenue growth 3Y15.59%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.22% on average over the next years. This is quite good.
  • Based on estimates for the next years, ANGN will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y34.37%
EPS Next 2Y25.74%
EPS Next 3Y18.22%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ANGN Yearly Revenue VS EstimatesANGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
ANGN Yearly EPS VS EstimatesANGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. ANGN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANGN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGN Price Earnings VS Forward Price EarningsANGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANGN Per share dataANGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ANGN's earnings are expected to grow with 18.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.74%
EPS Next 3Y18.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ANGN Dividend Analysis

5.1 Amount

  • No dividends for ANGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ANGN Fundamentals: All Metrics, Ratios and Statistics

ANGION BIOMEDICA CORP

NASDAQ:ANGN (6/1/2023, 8:00:00 PM)

After market: 0.9437 -0.06 (-5.63%)

1

+0.02 (+2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-10
Earnings (Next)08-14
Inst Owners10.12%
Inst Owner Change-31.79%
Ins Owners16.95%
Ins Owner Change0%
Market Cap30.11M
Revenue(TTM)653.00K
Net Income(TTM)-29.10M
Analysts43.33
Price Target1.53 (53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.96%
Min EPS beat(2)1.96%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)18.93%
Min EPS beat(4)1.96%
Max EPS beat(4)36.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 46.12
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0.02
BVpS1.32
TBVpS1.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 352.37%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20
Quick Ratio 20
Altman-Z -0.82
F-Score3
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)153.26%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.3%
EPS Next Y34.37%
EPS Next 2Y25.74%
EPS Next 3Y18.22%
EPS Next 5YN/A
Revenue 1Y (TTM)-97.79%
Revenue growth 3Y15.59%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y29.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.07%
OCF growth 3YN/A
OCF growth 5YN/A

ANGION BIOMEDICA CORP / ANGN Fundamental Analysis FAQ

What is the fundamental rating for ANGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to ANGN.


Can you provide the valuation status for ANGION BIOMEDICA CORP?

ChartMill assigns a valuation rating of 2 / 10 to ANGION BIOMEDICA CORP (ANGN). This can be considered as Overvalued.


Can you provide the profitability details for ANGION BIOMEDICA CORP?

ANGION BIOMEDICA CORP (ANGN) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ANGION BIOMEDICA CORP?

The Earnings per Share (EPS) of ANGION BIOMEDICA CORP (ANGN) is expected to grow by 34.37% in the next year.